Literature DB >> 10949826

Retroviral-mediated gene transfer in primary murine and human T-lymphocytes.

I Rivière1, H F Gallardo, A B Hagani, M Sadelain.   

Abstract

Recombinant retroviruses are efficient vectors for introducing genes into many mammalian cell types. They are useful in the context of clinical as well as experimental applications, owing to the ability to generate high-titer and helper-free viral stocks. Retroviral vectors are especially appropriate for the transduction of primary lymphocytes, because gene transfer is stable and mediated by nonimmunogenic vectors. Stable integration in chromosomes of cells undergoing clonal expansion ensures that the foreign genetic material will be faithfully transmitted to the cells' progeny. However, oncoretroviral vectors derived from murine leukemia viruses (MLV) require target cell division to integrate. Here we review factors that determine retroviral-mediated gene transfer efficiency in primary T-lymphocytes, in particular, T-cell activation status, viral receptor expression, and culture conditions.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10949826     DOI: 10.1385/MB:15:2:133

Source DB:  PubMed          Journal:  Mol Biotechnol        ISSN: 1073-6085            Impact factor:   2.695


  66 in total

1.  High-efficiency retroviral-mediated gene transfer into human and nonhuman primate peripheral blood lymphocytes.

Authors:  B A Bunnell; L M Muul; R E Donahue; R M Blaese; R A Morgan
Journal:  Proc Natl Acad Sci U S A       Date:  1995-08-15       Impact factor: 11.205

2.  Large-scale manufacturing of safe and efficient retrovirus packaging lines for use in immunotherapy protocols.

Authors:  D Farson; R McGuinness; T Dull; K Limoli; R Lazar; S Jalali; S Reddy; R Pennathur-Das; D Broad; M Finer
Journal:  J Gene Med       Date:  1999 May-Jun       Impact factor: 4.565

3.  Safe and efficient generation of recombinant retroviruses with amphotropic and ecotropic host ranges.

Authors:  O Danos; R C Mulligan
Journal:  Proc Natl Acad Sci U S A       Date:  1988-09       Impact factor: 11.205

Review 4.  Endogenous retroviruses and the evolution of resistance to retroviral infection.

Authors:  S Best; P R Le Tissier; J P Stoye
Journal:  Trends Microbiol       Date:  1997-08       Impact factor: 17.079

5.  Improved gene transfer into human lymphocytes using retroviruses with the gibbon ape leukemia virus envelope.

Authors:  J S Lam; M E Reeves; R Cowherd; S A Rosenberg; P Hwu
Journal:  Hum Gene Ther       Date:  1996-08-01       Impact factor: 5.695

6.  Identification of ETS domain proteins in murine T lymphocytes that interact with the Moloney murine leukemia virus enhancer.

Authors:  C V Gunther; B J Graves
Journal:  Mol Cell Biol       Date:  1994-11       Impact factor: 4.272

7.  Construction and properties of retrovirus packaging cells based on gibbon ape leukemia virus.

Authors:  A D Miller; J V Garcia; N von Suhr; C M Lynch; C Wilson; M V Eiden
Journal:  J Virol       Date:  1991-05       Impact factor: 5.103

8.  Antiviral activity of autocrine interferon-beta requires the presence of a functional interferon type I receptor.

Authors:  V Rousseau; I Cremer; E Lauret; I Rivière; M Aguet; E De Maeyer
Journal:  J Interferon Cytokine Res       Date:  1995-09       Impact factor: 2.607

9.  CD8+ T cells inhibit HIV replication in naturally infected CD4+ T cells. Evidence for a soluble inhibitor.

Authors:  J E Brinchmann; G Gaudernack; F Vartdal
Journal:  J Immunol       Date:  1990-04-15       Impact factor: 5.422

10.  Integration of murine leukemia virus DNA depends on mitosis.

Authors:  T Roe; T C Reynolds; G Yu; P O Brown
Journal:  EMBO J       Date:  1993-05       Impact factor: 11.598

View more
  6 in total

1.  Effective transduction of primary mouse blood- and bone marrow-derived monocytes/macrophages by HIV-based defective lentiviral vectors.

Authors:  Lingbing Zeng; Shiming Yang; Chengxiang Wu; Linbai Ye; Yuanan Lu
Journal:  J Virol Methods       Date:  2006-01-20       Impact factor: 2.014

2.  Quantitative imaging of the T cell antitumor response by positron-emission tomography.

Authors:  Purnima Dubey; Helen Su; Nona Adonai; Shouying Du; Antonio Rosato; Jonathan Braun; Sanjiv S Gambhir; Owen N Witte
Journal:  Proc Natl Acad Sci U S A       Date:  2003-01-23       Impact factor: 11.205

Review 3.  Editing of Endogenous Genes in Cellular Immunotherapies.

Authors:  Theodore L Roth
Journal:  Curr Hematol Malig Rep       Date:  2020-08       Impact factor: 3.952

4.  Dual targeting of ErbB2 and MUC1 in breast cancer using chimeric antigen receptors engineered to provide complementary signaling.

Authors:  Scott Wilkie; May C I van Schalkwyk; Steve Hobbs; David M Davies; Sjoukje J C van der Stegen; Ana C Parente Pereira; Sophie E Burbridge; Carol Box; Suzanne A Eccles; John Maher
Journal:  J Clin Immunol       Date:  2012-04-17       Impact factor: 8.317

Review 5.  T Cell Fitness and Autologous CAR T Cell Therapy in Haematologic Malignancy.

Authors:  Palak H Mehta; Salvatore Fiorenza; Rachel M Koldej; Anthony Jaworowski; David S Ritchie; Kylie M Quinn
Journal:  Front Immunol       Date:  2021-11-25       Impact factor: 7.561

6.  Incorporation of bacterial immunoevasins to protect cell therapies from host antibody-mediated immune rejection.

Authors:  Leila Peraro; Christopher M Bourne; Megan M Dacek; Enver Akalin; Jae H Park; Eric L Smith; David A Scheinberg
Journal:  Mol Ther       Date:  2021-07-02       Impact factor: 11.454

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.